No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Johannes Griss; Gudrun Ratzinger; Julia-Tatjana Maul; Wolfgang Weger; Diamant Thaçi; José Manuel Carrascosa; Constanze Jonak

doi:10.1002/ski2.263

No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Skin Health Dis. 2023 Jun 28;3(5):e263. doi: 10.1002/ski2.263. eCollection 2023 Oct.

Authors

Johannes Griss¹, Gudrun Ratzinger², Julia-Tatjana Maul^{3

4}, Wolfgang Weger⁵, Diamant Thaçi⁶, José Manuel Carrascosa⁷, Constanze Jonak¹

Affiliations

¹ Department of Dermatology Medical University of Vienna Vienna Austria.
² Department of Dermatology Medical University of Innsbruck Innsbruck Austria.
³ Department of Dermatology University Hospital Zurich Zurich Switzerland.
⁴ Faculty of Medicine University of Zurich Zurich Switzerland.
⁵ Department of Dermatology and Venereology Medical University of Graz Graz Austria.
⁶ Institute and Comprehensive Centre for Inflammation Medicine University of Lübeck Lübeck Germany.
⁷ Department of Dermatology Hospital Universitari Germans Trias i Pujol, IGTP, UAB Badalona Spain.

Abstract

In the literature there is no consensus on the correlation between early systemic intervention and better treatment response in psoriasis. Here we present data on the impact of disease duration (<5 years, 5-<10 years, and ≥10 years) on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis from the reSURFACE 1 and reSURFACE 2 phase 3 trials and the TRIBUTE phase 4 study. Overall, there was no significant effect of disease duration on the Psoriasis Area and Severity Index ≤1, ≤3, and ≤5, or the Dermatology Life Quality Index 0-1 response rates. Tildrakizumab was highly effective regardless of the psoriasis disease duration.